1. Introduction {#S1}
===============

Drug-induced liver injury (DILI) is the term used for liver damage that is caused by drugs, herbal agents or nutritional supplements ([@R30]; [@R76]). DILI has gained increasing attention in recent years ([@R62]), as it is one of the main causes for attrition during clinical and pre-clinical studies and the main reason for drug withdrawal from the market or for labeling with a black box warning ([@R4]; [@R15]; [@R53]; [@R63]). Thus, great effort has been invested towards elucidating the toxicological processes and mechanisms that result in manifestations of DILI ([@R75]). It is widely accepted that, together with metabolizing enzymes, liver transporters play an important role for maintaining the integrity and proper function of the liver, and also influence the ADMET (absorption, distribution, metabolism, excretion and toxicity) profile of drugs ([@R26]; [@R69]). Actually, there are several recent publications suggesting that inhibition of liver transporters might result in manifestations of DILI. For cholestasis in particular, strong evidence towards the role of the bile salt export pump (BSEP) ([@R2]; [@R23]; [@R55]; [@R60]; [@R75]; [@R74]; [@R77]) has been posed. There is also evidence for the multidrug resistance-associated protein 2 (MRP2) ([@R55]; [@R57]), breast cancer resistance protein (BCRP) ([@R55]; [@R57]), P-glycoprotein ([@R55]; [@R57]) and multidrug resistance-associated protein 3 and 4 (MRP3 and MRP4) ([@R55]; [@R57]; [@R77]) to be involved. For hyperbilirubinemia, another possible manifestation of hepatotoxicity, involvement of organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) ([@R12]; [@R71]), MRP2 ([@R71]) and to a smaller extent BCRP ([@R71]) is discussed.

Although *in vitro* predictive methods are efficient for many toxic endpoints, they are time-consuming and expensive ([@R6]; [@R78]). In addition, for assessing hepatotoxicity, experimental methods such as *in vitro* tests and animal models, have been shown to share low concordance (\< 50%) with human hepatotoxicity ([@R15]; [@R42]; [@R54]).

This led to the development of predictive computational methods, which are summarized in two recent reviews by ([@R17]) and ([@R25]). Although all these models generally perform quite well, they sometimes suffer from low statistical performance, imbalanced sensitivity vs specificity, or small data sets ([Table 1](#T1){ref-type="table"}).

In this study we generate *in silico* classification models for DILI by compiling multiple and diverse datasets from literature. We carefully curated these data regarding the chemotypes, as well as the accuracy of the class label. In addition, we are exploring the importance of hepatic transporter inhibition on DILI by using the predictions of a set of in-house *in silico* classification models as additional descriptors for the DILI model.

2. Methods {#S2}
==========

2.1. Data compilation {#S3}
---------------------

### 2.1.1. Training set {#S4}

Searching [@R59] (<http://www.ncbi.nlm.nih.gov/pubmed>), [@R32] (<https://www.google.at>) and [@R68] (<https://www.scopus.com/>) using the terms: "drug-induced liver injury", "DILI", "drug-induced hepatotoxicity" identified 9 unique datasets for human DILI/hepatotoxicity ([Table 2](#T2){ref-type="table"}).

For visualizing the data structures and for converting the names into structures Marvin from [@R13] (<http://www.chemaxon.com> 2013) was used.

### 2.1.2. External test sets {#S5}

After compiling the training set and generating the DILI model, we came across one more human DILI dataset that had initially escaped our attention ([@R41]). Additionally, there were two more datasets published after the model development ([@R18]; [@R51]) ([Table 3](#T3){ref-type="table"}).

All datasets (training set, the three external test sets and the merged test set) are provided in the [Supplementary material](#SM){ref-type="supplementary-material"}.

### 2.1.3. Chemical curation {#S6}

For each dataset we applied the following chemotype curation: Check for inorganic compounds using MOE 2014.09. ([@R45]) and remove any occurring.Using the Standardiser tool ([@R3]) created by Francis Atkinson; all salt parts and any compounds containing metals and rare or special atoms are removed from the dataset and the structures are standardized.Duplicates and permanently charged compounds are removed using MOE 2014.09. ([@R45]) Here we must note that stereoisomers, even if biologically can be considered as different compounds, were considered as duplicates in our study, since they give the exactly same vector of descriptors. If two (or more) stereoisomers are of the same class, only one was kept. If they were of different classes, all were removed.3D structures are generated using CORINA (version 3.4)([@R65]) and their energy is minimized with MOE 2014.09 ([@R45]), using default settings, but changing the gradient to 0.05 RMS kcal/mol/A^2^. Existing chirality is preserved.

### 2.1.4. Class-label curation {#S7}

Apart from the chemical curation of the data, we also apply careful curation regarding the class label of the compounds. In particular, after merging all individual datasets in one database, the majority of the compounds are present in more than one dataset. In case of conflicting class labels, the majority label is assigned to the compound. In case the class labels are equally distributed, the compound is considered as "ambiguous" and it is removed from the dataset. This leads to 1773 compounds, 794 positives and 979 negatives. In [Chart 1](#F1){ref-type="fig"} the overlap of compounds (positives and negatives) across the different amount of sources is depicted. It is notable that for the case of occurrence in all 9 sources, we have only positives for DILI, which is in accordance with the fact that negative results are less often reported.

However, the first modeling attempt of the dataset gave only moderate results. Re-analyzing the dataset revealed, that for several co-occurring compounds, even labeled as DILI negatives by majority vote, the Fourches source ([@R27]) was labeling them as positives. The Fourches dataset was compiled via text mining, a sophisticated but error-prone method ([@R9]; [@R84]). Therefore, in order to improve the dataset quality, all compounds that were coming solely from the Fourches dataset (227 compounds) were removed. Subsequently, all compounds coming from only a single source were removed, as they do not allow us to counter check the class label with at least one additional source. Following this concept leads to the removal of additional 584 compounds, which provides the final set of 966 compounds (500 positives and 466 negatives).

The differences in model performance after the class-label curation of the datasets is presented in the Supporting information ([Table S1](#SD4){ref-type="supplementary-material"}).

2.2. Generation of statistical models {#S8}
-------------------------------------

### 2.2.1. Algorithms used {#S9}

The 2-class classification models were built using the software package WEKA (version 3.7.12) ([@R34]). Performance of several base classifiers, such as logistic regression, tree methods (Random Forest and J48), Support Vector Machines (SMO in WEKA with polynomial, RBF and Puk kernels), Naïve Bayes, and k-nearest neighbors, several evaluating methods for attribute selection (AttributeSelectedClassifier), as well as for improving the statistical performance such as Bagging ([@R7]) and Boosting ([@R28]; [@R29]) were evaluated. All in all, Random Forest ([@R8]) with 100 trees was identified as the most promising classifier.

### 2.2.2. Molecular descriptors {#S10}

For both datasets, several types of molecular descriptors have been calculated: all 2D MOE descriptors (192 descriptors in total), the 3D Volsurf series of descriptors ([@R45]), PaDEL descriptors ([@R80]) and extended connectivity fingerprints of diameter 6 (ECFP6) using RDKit (Landrum). In general, the 2D MOE descriptors performed best.

In order to investigate the potential influence of transporter inhibition in DILI manifestation, we predicted the transporter inhibition profile of all compounds and used it as additional descriptors ([Table S2](#SD4){ref-type="supplementary-material"}). In particular, for OATP1B1 and 1B3 inhibition, we use our previously published models based on PaDEL descriptors ([@R39]), as implemented in eTOXlab ([@R10]). For BSEP inhibition, we useed the float predictions obtained from the model's implementation as KNIME workflow ([@R49]). Also for P-glycoprotein ([@R67]) and for BCRP ([@R48]) inhibition, the respective float prediction scores were used.

2.3. DILI model with open-source descriptors {#S11}
--------------------------------------------

Since MOE is a commercial software package, we also provide a free version of the model using exclusively open-source libraries. For this, the final model set-up (all 2D MOE descriptors and Random Forest with 100 trees) was taken and converted in the following way: descriptors were implemented in RDKit ([@R40]) (196 descriptors in total) and the Random Forest was implemented with the scikit-learn machine learning library for python ([@R58]). The script for training, cross-validating and using the model is provided as [Supplementary material](#SM){ref-type="supplementary-material"}.

2.4. Model validation {#S12}
---------------------

For model selection, 10-fold cross validation was used. The performance of each model was examined for accuracy, sensitivity, specificity, area under the curve (AUC) and precision. For the best models obtained, we performed 50 iterations by changing the cross-validation seed (for splitting the data within cross validation) and further performed a Welch (two-sample) *t*-test in R (<http://www.R-project.org/>) to assess whether the model performance for the different training data sets (after class label curation) is indeed significantly different. This was also done to compare whether the addition of the predicted transporter interaction profiles significantly improves model performance. The best models are further validated via external testing by using the validation datasets described above.

2.5. Applicability domain of the models {#S13}
---------------------------------------

The applicability domain was checked on KNIME with the Enalos nodes ([@R1]; [@R47]) that compute the applicability domain on the basis of the Euclidean distances ([@R81]). Additionally, we assessed to which extent the DILI datasets (both training and external test sets) were within the applicability domain of the transporters models, using the same procedure. The number of compounds within the model's applicability domain for each model and for each DILI dataset is provided in the Supporting information ([Table S3](#SD4){ref-type="supplementary-material"}).

3. Results and discussion {#S14}
=========================

3.1. Optimizing the training dataset -- the importance of curation {#S15}
------------------------------------------------------------------

Compiling the DILI dataset from the 9 data sources and performing the curation of the chemotypes and class labels according to majority vote initially lead to 1773 compounds. However, the first modeling attempts failed to yield models with acceptable performance. Analyzing the dataset revealed, that one source (Fourches) was compiled from text mining. Although text mining is a powerful approach for collecting data directly from narrative text, it is more prone to errors than manual extraction ([@R9]; [@R83]). Two examples are tocopherol and carnitine, which were reported as hepatotoxic only by the Fourches source. According to literature, those two compounds rather show a hepatoprotective effect against DILI caused by other drugs ([@R5]; [@R72]), than being hepatotoxic. Therefore, the compounds coming only from the Fouches dataset were completely removed. This reduction led to a new training set of 1547 compounds and improved the statistical performance of the resulting models (see [Table S3](#SD4){ref-type="supplementary-material"} in the Supplementary material). In order to further improve the dataset quality, we also removed all compounds that appear only in one source (581 compounds). In this case, it is not possible to double-check the class label, which definitely adds noise to the data. Indeed, the model trained on this dataset shows additional improvement ([Table S1](#SD4){ref-type="supplementary-material"}).

In order to evaluate if the difference between the models generated on the three datasets is statistically significant, 50 iterations of 10-fold cross validation were performed by changing the cross-validation seed followed by a two sample *t*-test ([Table S3](#SD4){ref-type="supplementary-material"}). As can be seen, all parameters apart from specificity generally increase with higher quality of the data sets. Especially sensitivity, which is of higher importance since we are dealing with a toxicity endpoint, presents a remarkable increase, rising from 46% to 68%.

Remarkably, the analysis also indicates no difference on the model performance whether using the transporters predictions as additional information or not.

3.2. DILI 2-class classification models {#S16}
---------------------------------------

For the final training dataset of 966 compounds, the best models are obtained using all 2D MOE descriptors. However, this restricts broader usage, as its application is conditional to a respective license for calculating the descriptors. In order to offer the model to the scientific community in open-source form, we rebuilt it using all 2D RDKit descriptors (196 descriptors in total; [Table 4](#T4){ref-type="table"}) and provide the respective python script.

As [Table 4](#T4){ref-type="table"} shows, the performance of the models is quite stable and satisfactory for cross validation. As can one see, there is no substantial difference between the model obtained via using transporters predictions as additional descriptors (model A), and the one built with only the 2D MOE descriptors (model B;), which is further confirmed by statistical testing (*p*-values \> 0.05). Furthermore, the open source model and the model built with proprietary descriptors can be considered equivalent, despite some minor changes for 10-fold cross validation and the external validation. The model remains robust also for external validation, with statistics values quite similar to those obtained by cross validation.

However, it has to be taken into account that the DILI dataset is based on toxicity reports. Thus, despite our complex workflow for curating the data, there still might be mislabeled compounds due to the drawbacks of the adverse event reporting system. Among these issues are: 1) under-reporting ([@R56]; [@R64]; [@R83]) due to the voluntary character of the system ([@R14]; [@R35]; [@R83]), 2) difficulty in finding human toxicity data (often proprietary and post-marketing data difficult to obtain) ([@R64]), 3) non-requirement of causality ([@R83]). The latter is quite serious in the contemporary era of polypharmacology, where many people, especially the elderly, receive more than one different medication. An indication of these drawbacks is the comparison of the class labels between overlapping compounds of the training and the test sets, as well as between the test sets themselves (formation of the merged external test set), which revealed contradiction of class labels in up to 20% of the compounds

3.3. Association of transporter inhibition profiles and DILI {#S17}
------------------------------------------------------------

There is ample evidence in literature for the association of selected liver transporters and DILI. This especially concerns BSEP ([@R2]; [@R23]; [@R55]; [@R60]; [@R75]; [@R74]; [@R77]), BCRP ([@R55]; [@R57]), P-glycoprotein ([@R55]; [@R57]), and OATP1B1/1B3 ([@R12]; [@R71]). This prompted us to introduce predicted inhibition profiles of these transporters into the feature matrix used for predicting DILI. However, we observed the same model performance for the models built with or without the transporter inhibition profile (Table 5, *p*-values \< 0.05).

A possible reason for this might relate to the fact that the transporter inhibition profiles are based on predictions rather than on experimental data. Even though the transport inhibition models are reliable (AUC values in [Table S2](#SD4){ref-type="supplementary-material"}) and most of the compounds of the DILI training set belong to the respective applicability domains ([Table S3](#SD4){ref-type="supplementary-material"}), one cannot rule out the possibility of mispredictions, which in turn add noise into the feature matrix. However, when comparing the accuracy of the transporter models with the experience gained in the data curation task, the noise added by wrong predictions is not expected to be far beyond the one present in the DILI class labels.

Furthermore, liver transporters have overlapping substrate and inhibitor profiles ([@R31]; [@R36]; [@R37]; [@R70]). Apart from that, the hepatic homeostasis systems have ways to compensate the inhibition of one transporter, by overexpression of another (e.g. OATP1B1/OATP1B3) ([@R22]; [@R38]). Thus, inhibition of solely one transporter might not have a great impact in the proper function of the hepatocyte. This is also reflected in the data: the training compounds that are predicted as inhibitors for up to three transporters are not particularly enriched with DILI positives (451 DILI-positives and 443 DILI-negatives), while compounds predicted to inhibit at least four transporters are more likely to be DILI-positives (49 DILI-positives and 23 DILI-negatives, *p*-value \< 0.01). Furthermore, liver transporters other than those included in this study may additionally play a role in DILI: the multidrug resistance-associated protein 2 (MRP2) ([@R52]; [@R55]; [@R57]), the multidrug resistance protein 3 (MDR3) ([@R11]; [@R57]) and MRP3 and MRP4 ([@R55]; [@R57]; [@R77]). Unfortunately, due to the lack of experimental data, it was not possible to develop and validate *in silico* models for these transporters in order to include them in the study.

Finally, it might be that the complexity of the DILI endpoint itself does not allow a strong association between liver transporter inhibition with DILI. Indeed, several other mechanisms produce hepatotoxicity ([@R75]): formation of reactive metabolites by cytochrome P450 ([@R20]; [@R66]; [@R73]), formation of glutathione adducts ([@R66]) and mitochondrial toxicity ([@R2]; [@R66]) are examples of mechanisms for causing DILI that are not specifically addressed in this study.

4. Conclusions {#S18}
==============

Drug-induced liver injury is a major issue for patients and, therefore, also for the process of drug discovery. Within the last decade, several attempts have taken place to predict DILI based on the chemical structure of a compound. In a more mechanistic based approach, one could also think on predicting DILI on basis of i.e. biological fingerprints. As these are usually not available for larger compound sets (at least not in the public domain), we included predicted liver-transporter interaction profiles as additional information. The liver transporter models have been developed in the course of the eTOX project and are available in eTOXsys, the integrated data mining and computational model environment established in the course of the project. Surprisingly, although the role of liver transporter for hepatotoxicity has clearly been demonstrated, this additional piece of information did not significantly improve model performance. Potential reasons for this are outlined above, and most probably the biological fingerprint needs to be substantially broadened by including additional transporter and enzymes to see a significant effect on model performance.

The predictivity of computational models heavily depends on the quality of the respective training data set and the domain it covers. In this work, we compiled datasets for DILI available in literature and carefully curated them both with respect to the chemical structures as well as for their class labels (DILI positive, DILI negative). This reduced the amount of compounds available for classification models from 1773 to 966, and in return remarkably increased the quality of the models developed. While in general bigger datasets are preferred for machine learning approaches, the current work once more stresses out the significance of data quality. However, there might be still an amount of mislabeled compounds, as the conflicting class labels for overlapping compounds in the training and test sets show. This further strengthens the tremendous need for industry-driven collaborative efforts such as the eTOX project to share data and to make them publicly available for mining and exploitation. Only large sets of high quality data will allow deriving predictive *in silico* models covering a broad chemical space.

Supplementary Material {#SM}
======================

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tox.2017.06.003>.
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###### 

Classification models for DILI reported in literature. Acc stands for accuracy, Sen for sensitivity, Spec for specificity, BA for balanced accuracy, CV for cross validation, EV for external validation and IV for internal validation.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference   Descriptors                                                                   Classification algorithm          Data used                                                     Reported performance
  ----------- ----------------------------------------------------------------------------- --------------------------------- ------------------------------------------------------------- ---------------------------------------------------
  [@R19]      2D molecular descriptor                                                       Ensemble recursive partitioning   382 drugs for CV                                              CV: 76% Acc; 76% Sen; 75% Spec

                                                                                                                              54 drugs for EV                                               EV: 81% Acc; 70% Sen; 90% Spec

  [@R21]      Radial distribution function                                                  Linear discriminant analysis      74 drugs for CV                                               CV: 84% Acc; 78% Sen; 90% Spec

              molecular descriptors                                                                                           13 drugs for EV                                               EV: 82% Acc

  [@R46]      Molecular descriptors                                                         4 commercial QSAR programs        \~1600 drugs for CV                                           CV: 39% Sen; 87% Spec

                                                                                                                              18 drugs for EV                                               EV: 89% Sen

  [@R64]      topological\                                                                  k-nearest neighbor                37 drugs for EV                                               84% Acc; 74% Sen; 94% Spec
              indices of molecular structures (MolConnZ) and Dragon molecular descriptors                                                                                                   

  [@R27]      2D fragments and Dragon                                                       Support vector machine            531 drugs for CV 18 compounds for EV                          CV: 62--68% Accs

              molecular descriptors                                                                                                                                                         EV: 78% Acc

  [@R24]      extended connectivity functional                                              Linear discriminant analysis      295 compound for CV                                           CV: 59% ACC; 53% Sen; 65% Spec

              class fingerprints of maximum diameter 6 (ECFC_6)                                                               237 compounds for EV                                          EV: 60% Acc; 56% Sen; 67% Spec

  [@R41]      PaDEL molecular descriptor                                                    Ensemble of mixed learning        1087 compounds for CV                                         CV: 68% Accs; 67% Sen; 70% Spec

                                                                                                                              120 compounds for EV                                          EV: 75% Acc; 82% Sen; 65% Spec

  [@R42]      functional class                                                              Bayesian models                   888 drugs for training3 data sets with 40--148 drugs for EV   EV: 60--70% Accs

              fingerprints (FCFP_6)                                                                                                                                                         

  [@R16]      Mold2 chemical descriptor                                                     Decision Forest                   197 drugs for CV                                              CV: 70% Acc

                                                                                                                              Three data sets with\                                         EV: 62--69% Accs
                                                                                                                              190--348 drugs for EV                                         

  [@R43]      physicochemical descriptors and fingerprints                                  Ensemble classifier               677 compounds for CV                                          81% BA; 66% Sen; 95% Spec

  [@R50]      physicochemical descriptors and fingerprints                                  Ensemble classifier               677 compounds for CV                                          81% BA; 66% Sen; 95% Spec

  [@R50]      ISIDA fragment descriptors                                                    SVM                               424 drugs for CV                                              66% BA

  [@R79]      Encoding layers based on SMILES, PaDEL descriptors                            Deep Learning                     190, 475 & 1065 compounds for CV                              CV: 70--88% Accs; 70--90% Sens; 70--87% Specs

                                                                                                                              185,320, 236,198 & 119 compounds for EV                       EV: 62--87% Accs; 62--83% Sens; 62--93% Specs

  [@R51]      2D and 3D physicochemical descriptors                                         SVM with a genetic algorithm      3712 compounds for training                                   IV: 75% Acc; 73% AUC

                                                                                                                              221 compounds for IV                                          

                                                                                                                              269 compounds for EV                                          

  [@R82]      FP4 fingerprints                                                              SVM                               1317 compounds for training                                   Training set: 66% Acc; 85% Sen; 34% Spec; 55% AUC

                                                                                                                              88 compounds for EV                                           EV: 75% Acc; 93% Sen; 38% Spec; 61% AUC
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Description of the sources upon which the training set was built. In number of compounds, "+" denotes the number of DILI-positive compounds and "−" the number of negative compounds. These numbers correspond to the number of compounds remaining after data curation in a source by source basis.

  Source name   Type of data                       Number of compounds   Label choice
  ------------- ---------------------------------- --------------------- ----------------------------------------------------------------------
  [@R53]        *In vitro* cell-based assay        132 (100+/32−)        "severely" and "moderately" toxic are considered positives.
  [@R64]        FDA reports database               382 (75+/307−)        Authors classification
  [@R27]        Text mining                        902 (620+/282−)       Authors classification
  [@R33]        Compilation of published data      385 (252+/133−)       Authors classification
  [@R24]        Clinical data for hepatotoxicity   499 (294+/205−)       Authors classification
  [@R15]        FDA-approved labels                279 (218+/61−)        "most DILI concern" and "less DILI concern" are considered positives
  [@R42]        SIDER_2 database                   835 (188+/647−)       Authors classification
  [@R83]        Post-marketing safety data         1948 (651+/1297−)     Authors classification, keeping only highest class certainty
  [@R44]        LiverTox database                  583 (409+/174−)       "hepatotoxic" and "possible hepatotoxic" are considered positives

###### 

Description of the sources upon which the test set was built. In number of compounds, "+" denotes the number of DILI-positive compounds and "−" the number of negative compounds. These numbers correspond to the number of compounds remaining after data curation in a source by source basis.

  Source name   Type of data                                                                                                Number of compounds   Label choice
  ------------- ----------------------------------------------------------------------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------------
  [@R41]        Micromedex reports of adverse reactions                                                                     341 (221+/120−)       Authors classification
  [@R51]        Compilation of public data, data from PharmaPendium and Leadscope                                           921 (519+/402−)       Authors classification
  [@R18]        Compilation of public data and LiverTox                                                                     96 (50+/46−)          "most DILI concern" and "less DILI concern" are considered positives, "verified no DILI concern" as negatives
  Merged        The 3 external datasets were merged and the common compounds with contradictory class labels were removed   996 (541+/455−)       Maintenance of the class labels of the original external test sets

###### 

Statistical performance of the final Random Forest (100 trees) model A) using all 2D MOE descriptors and transporter predictions (DILI_MOE_transp_RF model) or B) using only the 2D MOE descriptors (DILI_MOE_RF model) and the C) open source model (DILI_RDKit \_RF100).

                                                                  Accuracy      Sensitivity   Specificity   AUC           Precision
  --------------------------------------------------------------- ------------- ------------- ------------- ------------- -------------
  A\) DILI_MOE_transp \_RF100                                                                                             
  10-fold CV (average +/− standard deviation for 50 iterations)   0.65 ± 0.01   0.68 ± 0.01   0.61 ± 0.01   0.69 ± 0.01   0.65 ± 0.01
  Mulliner 921 cpds                                               0.57          0.63          0.50          0.59          0.62
  Liew 341 cpds                                                   0.67          0.72          0.56          0.71          0.75
  Chen 96 cpds                                                    0.59          0.54          0.65          0.61          0.63
  Merged test set 966cpds                                         0.59          0.68          0.50          0.62          0.62
  B\) DILI\_ MOE \_RF100                                                                                                  
  10-fold CV (average +/− standard deviation for 50 iterations)   0.65 ± 0.01   0.68 ± 0.01   0.61 ± 0.01   0.69 ± 0.01   0.65 ± 0.01
  Mulliner 921 cpds                                               0.58          0.60          0.55          0.59          0.63
  Liew 341 cpds                                                   0.68          0.68          0.67          0.71          0.79
  Chen 96 cpds                                                    0.63          0.56          0.70          0.66          0.67
  Merged test set 966cpds                                         0.60          0.64          0.56          0.62          0.63
  C\) DILI_RDKit_RF100                                                                                                    
  10-fold CV (average +/− standard deviation for 50 iterations)   0.64 ± 0.01   0.70 ± 0.01   0.57 ± 0.01   0.69 ± 0.01   0.63 ± 0.01
  Mulliner 921 cpds                                               0.60          0.64          0.54          0.62          0.64
  Liew 332 cpds                                                   0.67          0.72          0.56          0.71          0.72
  Chen 95 cpds                                                    0.64          0.64          0.64          0.73          0.64
  Merged test set 966cpds                                         0.60          0.67          0.52          0.64          0.63

*Notes:* The number of compounds for the external datasets is slightly different for the predictions on model C because for some compounds (peptides), some descriptor values computed by RDKit were too large to be handled by the machine learning algorithm.
